CS276556B6 - Pharmaceutical with a controllable bio-disposal of active component - Google Patents
Pharmaceutical with a controllable bio-disposal of active component Download PDFInfo
- Publication number
- CS276556B6 CS276556B6 CS903838A CS383890A CS276556B6 CS 276556 B6 CS276556 B6 CS 276556B6 CS 903838 A CS903838 A CS 903838A CS 383890 A CS383890 A CS 383890A CS 276556 B6 CS276556 B6 CS 276556B6
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- oxodipine
- tablet
- pharmaceutical composition
- composition according
- prosobel
- Prior art date
Links
- 229950009982 oxodipine Drugs 0.000 claims description 49
- MSOAVHHAZCMHDI-UHFFFAOYSA-N oxodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC2=C1OCO2 MSOAVHHAZCMHDI-UHFFFAOYSA-N 0.000 claims description 48
- 239000002775 capsule Substances 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 11
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 229960001597 nifedipine Drugs 0.000 claims description 5
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 5
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 102000014171 Milk Proteins Human genes 0.000 claims description 2
- 108010011756 Milk Proteins Proteins 0.000 claims description 2
- 235000021239 milk protein Nutrition 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000006104 solid solution Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- -1 fatty acid ester Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009512 pharmaceutical packaging Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8910605A FR2650502B1 (fr) | 1989-08-07 | 1989-08-07 | Nouvelle forme galenique orale ameliorant la biodisponibilite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS383890A3 CS383890A3 (en) | 1992-06-17 |
| CS276556B6 true CS276556B6 (en) | 1992-06-17 |
Family
ID=9384532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS903838A CS276556B6 (en) | 1989-08-07 | 1990-08-03 | Pharmaceutical with a controllable bio-disposal of active component |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0412877A1 (OSRAM) |
| JP (1) | JPH0377819A (OSRAM) |
| KR (1) | KR910004181A (OSRAM) |
| CN (1) | CN1049455A (OSRAM) |
| AU (1) | AU631235B2 (OSRAM) |
| CA (1) | CA2022447A1 (OSRAM) |
| CS (1) | CS276556B6 (OSRAM) |
| DD (1) | DD297332A5 (OSRAM) |
| DE (1) | DE4023136A1 (OSRAM) |
| FI (1) | FI903885A7 (OSRAM) |
| FR (1) | FR2650502B1 (OSRAM) |
| GB (1) | GB2234898A (OSRAM) |
| HU (1) | HU204997B (OSRAM) |
| IE (1) | IE902629A1 (OSRAM) |
| IL (1) | IL95105A0 (OSRAM) |
| IN (1) | IN170789B (OSRAM) |
| LU (1) | LU87777A1 (OSRAM) |
| MA (1) | MA21923A1 (OSRAM) |
| NO (1) | NO903442L (OSRAM) |
| NZ (1) | NZ234593A (OSRAM) |
| OA (1) | OA09301A (OSRAM) |
| PE (1) | PE491A1 (OSRAM) |
| PT (1) | PT94823A (OSRAM) |
| TN (1) | TNSN90111A1 (OSRAM) |
| ZA (1) | ZA905886B (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2128244C (en) * | 1992-01-17 | 1998-09-22 | Jens-Christian Wunderlich | Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies |
| DE4221880A1 (de) * | 1992-07-03 | 1994-01-05 | Alfatec Pharma Gmbh | Feste und flüssige Lösungen von schwer wasserlöslichen Arzneistoffen |
| KR20030089147A (ko) * | 2002-05-16 | 2003-11-21 | 슈라펫 주식회사 | 애완동물용 급수통 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE854414C (de) * | 1949-04-26 | 1952-11-04 | Dieter Dr Med Ellenbeck | Verfahren zur Herstellung von injizierbaren Loesungen von an sich mehr oder weniger schwer loeslichen Arzneimitteln |
| GB715874A (en) * | 1952-10-03 | 1954-09-22 | Horlicks Ltd | A tablet for use in treating peptic ulcers |
| GB906422A (en) * | 1958-05-02 | 1962-09-19 | Wellcome Found | Improvements in and relating to prolonged acting pharmaceutical preparations |
| US3015611A (en) * | 1959-08-25 | 1962-01-02 | Nysco Lab Inc | Low density whey-bound tablets |
| GB1063872A (en) * | 1962-08-11 | 1967-03-30 | Wellcome Found | Improvements in and relating to prolonged acting pharmaceutical compositions |
| US3594467A (en) * | 1968-10-09 | 1971-07-20 | Richardson Merrell Inc | Long-lasting troche |
| US3922379A (en) * | 1973-12-17 | 1975-11-25 | Abbott Lab | Microencapsulation process |
| US4107288A (en) * | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| CA1184492A (en) * | 1981-01-14 | 1985-03-26 | Masataka Morishita | Preparation having excellent absorption property |
| FR2524312B1 (fr) * | 1982-04-01 | 1985-10-04 | Tech Cuir Centre | Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif |
| JPS59101423A (ja) * | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | 新規なニフエジピン固形製剤 |
| CA1249968A (en) * | 1984-04-05 | 1989-02-14 | Kazuo Kigasawa | Ointment base |
| US4670251A (en) * | 1984-05-30 | 1987-06-02 | Igene Biotechnology, Inc. | Microcrystalline tableting excipient derived from whey |
| NZ217844A (en) * | 1985-10-11 | 1989-10-27 | Sumitomo Pharma | A sustained release pharmaceutical composition containing silicone elastomer and an albumin |
| IL78017A (en) * | 1986-03-03 | 1989-06-30 | Yissum Res Dev Co | Sustained release tablets of theophylline |
| DE3702105A1 (de) * | 1987-01-24 | 1988-08-04 | Bayer Ag | Parenterale loesung |
| US5051406A (en) * | 1987-03-04 | 1991-09-24 | Nippon Hypox Laboratories Incorporated | Pharmaceutical composition using albumin as a carrier and process for producing the same |
| CA1324083C (en) * | 1987-03-09 | 1993-11-09 | Tetsu Miyoshi | Pharmaceutical preparations containing non-steroidal anti-inflammatory agents |
| DK179687D0 (da) * | 1987-04-08 | 1987-04-08 | Farma Food As | Praeparat |
| EP0307097B1 (en) * | 1987-09-08 | 1993-06-09 | Takeda Chemical Industries, Ltd. | Water-insolubilized cytokines |
-
1989
- 1989-08-07 FR FR8910605A patent/FR2650502B1/fr not_active Expired - Fee Related
-
1990
- 1990-07-17 IL IL95105A patent/IL95105A0/xx unknown
- 1990-07-18 IE IE262990A patent/IE902629A1/en unknown
- 1990-07-19 IN IN578/MAS/90A patent/IN170789B/en unknown
- 1990-07-20 DE DE4023136A patent/DE4023136A1/de not_active Withdrawn
- 1990-07-20 NZ NZ234593A patent/NZ234593A/en unknown
- 1990-07-26 ZA ZA905886A patent/ZA905886B/xx unknown
- 1990-07-26 PT PT94823A patent/PT94823A/pt not_active Application Discontinuation
- 1990-08-01 LU LU87777A patent/LU87777A1/fr unknown
- 1990-08-01 CA CA002022447A patent/CA2022447A1/fr not_active Abandoned
- 1990-08-01 EP EP90402199A patent/EP0412877A1/fr not_active Withdrawn
- 1990-08-02 MA MA22193A patent/MA21923A1/fr unknown
- 1990-08-03 PE PE1990173269A patent/PE491A1/es unknown
- 1990-08-03 GB GB9017144A patent/GB2234898A/en not_active Withdrawn
- 1990-08-03 CS CS903838A patent/CS276556B6/cs unknown
- 1990-08-04 KR KR1019900011979A patent/KR910004181A/ko not_active Withdrawn
- 1990-08-06 DD DD90343250A patent/DD297332A5/de not_active IP Right Cessation
- 1990-08-06 AU AU60239/90A patent/AU631235B2/en not_active Ceased
- 1990-08-06 FI FI903885A patent/FI903885A7/fi not_active Application Discontinuation
- 1990-08-06 NO NO90903442A patent/NO903442L/no unknown
- 1990-08-06 CN CN90106874A patent/CN1049455A/zh active Pending
- 1990-08-06 JP JP2209061A patent/JPH0377819A/ja active Pending
- 1990-08-06 OA OA59830A patent/OA09301A/xx unknown
- 1990-08-06 HU HU904909A patent/HU204997B/hu not_active IP Right Cessation
- 1990-08-07 TN TNTNSN90111A patent/TNSN90111A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| OA09301A (fr) | 1992-09-15 |
| NO903442D0 (no) | 1990-08-06 |
| IE902629A1 (en) | 1991-02-27 |
| IL95105A0 (en) | 1991-06-10 |
| PT94823A (pt) | 1991-04-18 |
| GB9017144D0 (en) | 1990-09-19 |
| IN170789B (OSRAM) | 1992-05-23 |
| DD297332A5 (de) | 1992-01-09 |
| FR2650502B1 (fr) | 1994-05-27 |
| HUT55230A (en) | 1991-05-28 |
| FR2650502A1 (fr) | 1991-02-08 |
| CN1049455A (zh) | 1991-02-27 |
| CS383890A3 (en) | 1992-06-17 |
| TNSN90111A1 (fr) | 1991-03-05 |
| GB2234898A (en) | 1991-02-20 |
| CA2022447A1 (fr) | 1991-02-08 |
| HU204997B (en) | 1992-03-30 |
| NZ234593A (en) | 1993-04-28 |
| KR910004181A (ko) | 1991-03-28 |
| EP0412877A1 (fr) | 1991-02-13 |
| JPH0377819A (ja) | 1991-04-03 |
| HU904909D0 (en) | 1991-01-28 |
| ZA905886B (en) | 1991-04-24 |
| FI903885A7 (fi) | 1991-02-08 |
| PE491A1 (es) | 1991-01-26 |
| AU6023990A (en) | 1991-02-07 |
| NO903442L (no) | 1991-02-08 |
| MA21923A1 (fr) | 1991-04-01 |
| AU631235B2 (en) | 1992-11-19 |
| LU87777A1 (fr) | 1990-12-11 |
| FI903885A0 (fi) | 1990-08-06 |
| DE4023136A1 (de) | 1991-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0142561B1 (en) | Long-acting nifedipine preparation | |
| NZ201008A (en) | Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient | |
| HU230771B1 (hu) | Késleltetett leadású vitaminkészítmény | |
| MXPA03005883A (es) | Composiciones farmaceuticas que comprenden maleato de amlodipina. | |
| AU2001290354A1 (en) | Pharmaceutical compositions comprising amlodipine maleate | |
| US6100274A (en) | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions | |
| EA019614B1 (ru) | Усовершенствованная фармацевтическая композиция, содержащая антагонист дигидропиридинкальциевого канала, и способ ее получения | |
| PT85128B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo, como ingrediente activo, 4-(1-metil-4-piperidilideno)-4h-benzo-{4,5}ciclohepta{1,2-b}tiofeno--10(9h)-ona | |
| JPH03500288A (ja) | 徐放性ニフェジピン製剤 | |
| CA2764172A1 (en) | A thrombin receptor antagonist and clopidogrel fixed dose tablet | |
| WO2007128495A2 (en) | Solid pharmaceutical composition of gabapentin | |
| JPS63310827A (ja) | ニコチン酸誘導体を主剤とする徐放性製剤 | |
| CA2325014C (en) | 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine oral compositions | |
| CS276556B6 (en) | Pharmaceutical with a controllable bio-disposal of active component | |
| KR100590622B1 (ko) | 레보시멘단과 알긴산을 포함하는 안정한 조성물 | |
| WO2008149201A2 (en) | Stable pharmaceutical composition | |
| CZ79593A3 (en) | Antitussive preparation | |
| KR950007229B1 (ko) | 케토티펜을 함유한 약학적 조성물 | |
| JP2023183350A (ja) | ラコサミド固形製剤 | |
| WO2024200335A1 (en) | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32 h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide | |
| JPS59184126A (ja) | ２，６−ビス−ジエタノ−ルアミノ−４，８−ジピペリジノ−ピリミド〔５，４−ｄ〕ピリミジン含有医薬組成物 | |
| CZ12025U1 (cs) | Farmaceutické prostředky obsahující amlodipinmaleát a jejich použití | |
| KR20030070594A (ko) | 암로디핀 말레에이트를 포함하는 약학 조성물 | |
| KR20080037425A (ko) | 광 안정성이 향상된 조성물 | |
| HK1001822B (en) | Medicinal form for oral application for the once-a-day treatment of hypertension by diltiazem hydrochloride |